FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894834281> ?p ?o ?g. }

• W2894834281 endingPage "1255" @default.
• W2894834281 startingPage "1254" @default.
• W2894834281 abstract "The authors of the recent American College of Medical Genetics and Genomics clinical practice resource on the care of adults with neurofibromatosis type 1 (NF1) (ref. 1.Stewart D.R. Korf B.R. Nathanson K.L. Stevenson D.A. Yohay K. Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).10.1038/gim.2018.28Genet Med. 2018; 20: 671-682Google Scholar) are to be commended for their comprehensive publication. However, an important comorbidity that affects patients with NF1 was left out and remains generally underrecognized by clinicians: growth hormone (GH) excess leading to either clinical or subclinical gigantism or acromegaly. These two disorders represent a continuum of clinical manifestations and are distinguished by the status of the epiphyseal growth plates with respect to GH excess. GH excess is generally a rare disease in children and adults and is usually caused by a benign GH-secreting pituitary adenoma (somatotropinoma, with co-secretion of prolactin or PRL, it is referred to as somatomammotropinoma), pituitary hyperplasia secreting GH or PRL or both, or another neuroendocrine tumor elsewhere, releasing growth factors. GH excess likely affects patients with NF1 at higher rates, and across all ages, potentially increasing their oncological risk or growth of an existing tumor. This association was first recognized in the early 1900s and a few cases have been reported to date.2.Cambiaso P. Galassi S. Palmiero M. et al.Growth hormone excess in children with neurofibromatosis type-1 and optic glioma.1:CAS:528:DC%2BC2sXhtlemt7jF10.1002/ajmg.a.38308Am J Med Genet A. 2017; 173: 2353-2358Google Scholar In the largest study on children with NF1 and overgrowth, Cambiaso et al. found that 10% of their population with NF1 had abnormalities in their GH axis, consistent with GH excess.2.Cambiaso P. Galassi S. Palmiero M. et al.Growth hormone excess in children with neurofibromatosis type-1 and optic glioma.1:CAS:528:DC%2BC2sXhtlemt7jF10.1002/ajmg.a.38308Am J Med Genet A. 2017; 173: 2353-2358Google Scholar Interestingly, all of their affected patients had a tumor involving the optic chiasm, without pituitary involvement, as previously described.2.Cambiaso P. Galassi S. Palmiero M. et al.Growth hormone excess in children with neurofibromatosis type-1 and optic glioma.1:CAS:528:DC%2BC2sXhtlemt7jF10.1002/ajmg.a.38308Am J Med Genet A. 2017; 173: 2353-2358Google Scholar Optic pathway tumors (OPTs) are usually identified on magnetic resonance image (MRI) scans as a contrast enhancing mass. Although the mechanism underlying GH excess in NF1 is unknown, it has been postulated that loss of somatostatinergic inhibition from OPTs, particularly those involving the hypothalamic and sellar regions, leads to a dysregulated GH secretion pattern. Others have proposed the presence of overactive GH-releasing hormone (normally produced in the arcuate nucleus of the hypothalamus) in OPTs, although staining for this hormone was negative in some cases. The diagnosis of GH excess in NF1 should be suspected in children with accelerated linear growth, clinical features of gigantism such as enlargement of the hands and feet, soft-tissue thickening, prognathism, coarse facial features, presence of OPTs, or worsening of clinical features such as neurofibromas, pain, or endocrinopathies. Adults with GH excess and NF1 may also present with progressive clinical or coarse features suggestive of acromegaly, or worsening neurofibromas, pain, or endocrinopathies. Although short adult height is an important characteristic of NF1, clinicians should not be deterred from screening short individuals with NF1 for GH excess, particularly if the aforementioned features of overgrowth exist. Biochemical screening for GH excess in NF1 should follow existing guidelines for the diagnosis of gigantism and acromegaly. This includes measurement of serum IGF-1 and GH levels that can be paired in a random sample. Normal IGF-1 and GH levels may be encountered in patients with NF1 and suspected gigantism and/or acromegaly; in such cases, serial overnight GH sampling may be performed in specialized centers.3.Hannah-Shmouni F, Beckers P, Trivellin G, Lyssikatos C, Josefson JL, Lodish M, Stratakis CA. Neurofibromatosis 1 and growth hormone excess. 2016 Endocrine Society Meeting Abstracts. Endocr Rev 2016; 37:5-6Google Scholar GH excess is confirmed with elevated IGF-1 and lack of GH suppression to levels <1 ng/mL after the oral glucose tolerance test. Once confirmed, imaging of the pituitary, suprasellar, and optic tracts is recommended for evaluating pituitary lesions, hypothalamic infiltrations, or OPT, respectively. Recently, we evaluated ten subjects with NF1 who were referred to the National Institutes of Health for workup of overgrowth.3.Hannah-Shmouni F, Beckers P, Trivellin G, Lyssikatos C, Josefson JL, Lodish M, Stratakis CA. Neurofibromatosis 1 and growth hormone excess. 2016 Endocrine Society Meeting Abstracts. Endocr Rev 2016; 37:5-6Google Scholar Six children (median age = 3.9 years, range 4-10), one adolescent, and three adults (median age = 33 years, range 29-52) with NF1 had GH excess that was confirmed by failure to suppress GH on oral glucose tolerance tests (n = 9) and frequent overnight sampling of GH levels (n = 6) (ref. 3.Hannah-Shmouni F, Beckers P, Trivellin G, Lyssikatos C, Josefson JL, Lodish M, Stratakis CA. Neurofibromatosis 1 and growth hormone excess. 2016 Endocrine Society Meeting Abstracts. Endocr Rev 2016; 37:5-6Google Scholar). We showed pattern variability of serial overnight GH secretion in this group and confirmed a link between pituitary tumorigenesis, NF1, and GH excess.3.Hannah-Shmouni F, Beckers P, Trivellin G, Lyssikatos C, Josefson JL, Lodish M, Stratakis CA. Neurofibromatosis 1 and growth hormone excess. 2016 Endocrine Society Meeting Abstracts. Endocr Rev 2016; 37:5-6Google Scholar One adult subject had radiographic evidence of pituitary hyperplasia (voluminous pituitary gland) and overnight secretion of GH and PRL (somatomammotroph hyperplasia),3.Hannah-Shmouni F, Beckers P, Trivellin G, Lyssikatos C, Josefson JL, Lodish M, Stratakis CA. Neurofibromatosis 1 and growth hormone excess. 2016 Endocrine Society Meeting Abstracts. Endocr Rev 2016; 37:5-6Google Scholar as also seen in McCune-Albright syndrome, Carney complex, and multiple endocrine neoplasia type 1. Our data underline the need for early recognition and investigation for gigantism or acromegaly in patients with NF1, including a careful and thorough investigation of the pituitary gland through imaging. Evaluation of GH excess in NF1 is a forgotten comorbidity that is important to address in clinical practice and future guidelines, which has screening and treatment implications for the management of children and adults with NF1. Stratakis laboratory has received a research grant from Pfizer Inc. for studies related to the pathophysiology of GH secretion" @default.
• W2894834281 created "2018-10-12" @default.
• W2894834281 creator A5031897654 @default.
• W2894834281 creator A5076156629 @default.
• W2894834281 date "2019-05-01" @default.
• W2894834281 modified "2023-09-25" @default.
• W2894834281 title "Growth hormone excess in neurofibromatosis 1" @default.
• W2894834281 cites W2510612610 @default.
• W2894834281 doi "https://doi.org/10.1038/s41436-018-0312-1" @default.
• W2894834281 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30283094" @default.
• W2894834281 hasPublicationYear "2019" @default.
• W2894834281 type Work @default.
• W2894834281 sameAs 2894834281 @default.
• W2894834281 citedByCount "12" @default.
• W2894834281 countsByYear W28948342812018 @default.
• W2894834281 countsByYear W28948342812019 @default.
• W2894834281 countsByYear W28948342812020 @default.
• W2894834281 countsByYear W28948342812021 @default.
• W2894834281 countsByYear W28948342812022 @default.
• W2894834281 countsByYear W28948342812023 @default.
• W2894834281 crossrefType "journal-article" @default.
• W2894834281 hasAuthorship W2894834281A5031897654 @default.
• W2894834281 hasAuthorship W2894834281A5076156629 @default.
• W2894834281 hasBestOaLocation W28948342811 @default.
• W2894834281 hasConcept C126322002 @default.
• W2894834281 hasConcept C134018914 @default.
• W2894834281 hasConcept C2778984943 @default.
• W2894834281 hasConcept C2984496839 @default.
• W2894834281 hasConcept C54355233 @default.
• W2894834281 hasConcept C71315377 @default.
• W2894834281 hasConcept C71924100 @default.
• W2894834281 hasConcept C86803240 @default.
• W2894834281 hasConceptScore W2894834281C126322002 @default.
• W2894834281 hasConceptScore W2894834281C134018914 @default.
• W2894834281 hasConceptScore W2894834281C2778984943 @default.
• W2894834281 hasConceptScore W2894834281C2984496839 @default.
• W2894834281 hasConceptScore W2894834281C54355233 @default.
• W2894834281 hasConceptScore W2894834281C71315377 @default.
• W2894834281 hasConceptScore W2894834281C71924100 @default.
• W2894834281 hasConceptScore W2894834281C86803240 @default.
• W2894834281 hasIssue "5" @default.
• W2894834281 hasLocation W28948342811 @default.
• W2894834281 hasLocation W28948342812 @default.
• W2894834281 hasOpenAccess W2894834281 @default.
• W2894834281 hasPrimaryLocation W28948342811 @default.
• W2894834281 hasRelatedWork W1991634850 @default.
• W2894834281 hasRelatedWork W1997759048 @default.
• W2894834281 hasRelatedWork W2010645160 @default.
• W2894834281 hasRelatedWork W2021502319 @default.
• W2894834281 hasRelatedWork W2027210979 @default.
• W2894834281 hasRelatedWork W2042044567 @default.
• W2894834281 hasRelatedWork W2049266444 @default.
• W2894834281 hasRelatedWork W2069420617 @default.
• W2894834281 hasRelatedWork W2079613337 @default.
• W2894834281 hasRelatedWork W2164661085 @default.
• W2894834281 hasVolume "21" @default.
• W2894834281 isParatext "false" @default.
• W2894834281 isRetracted "false" @default.
• W2894834281 magId "2894834281" @default.
• W2894834281 workType "article" @default.